Action MEDGENICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Medgenics, Inc. Nyse

Actions

US58436Q2030

Cours en clôture Nyse
Autres places de cotation
- USD - Graphique intraday de Medgenics, Inc.
2018 Transcript : Aevi Genomic Medicine, Inc. - Special Call
2018 Transcript : Aevi Genomic Medicine, Inc., Q4 2017 Earnings Call, Mar 13, 2018

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination
PR
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
PR
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference
PR
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
PR
Aevi Genomic Medicine : Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD
PR
Aevi Genomic Medicine : to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD
PR
Aevi Genomic Medicine : Reports Third Quarter 2018 Financial Results and Provides Business Update
PR
Aevi Genomic Medicine : Announces Completion of Enrollment for Part B of the ASCEND Trial
PR
Aevi Genomic Medicine : to Present at the H.C. Wainwright 20th Annual Global Investment Conference
PR
Aevi Genomic Medicine : Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
PR
Aevi Genomic Medicine : Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
PR
Aevi Genomic Medicine : Reports Second Quarter 2018 Financial Results and Provides Business Update
PR
Aevi Genomic Medicine, Inc. : Announces Novel Co-crystal Version of AEVI-001
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action
  4. Action
  5. Actualités Medgenics, Inc.
  6. Communiqués